THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

Sehnalová, Irena

doi:10.31925/farmacia.2020.3.25

Cited by 5 publications

(6 citation statements)

References 23 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, because regular screening has increased so much within the past 20-30 years, the death rate of CRC has been decreasing [9]. And of course, the decrease in death rate is also because of improved treatment options and targeted therapies [12]. Similarly, dietary and chemopreventive measures also play a role in decreasing the overall incidence of CRC [13,14].…”

Section: Introductionmentioning

confidence: 99%

Colorectal Cancer Screening: Impact of COVID-19 Pandemic and Possible Consequences

Harber

Zeidan

Aslam

2021

Life

View full text Add to dashboard Cite

Colonoscopy procedure has been the key screening method to detect colorectal cancer (CRC). As a fatal disease, CRC needs early detection. The COVID-19 pandemic caused screening tests (colonoscopy) to be halted and delayed. As a result, there could be dire consequences such as later-stage or missed diagnosis or greater mortality. This report will analyze scientific literature pertaining to interrupted CRC screenings due to COVID-19 while drawing historical parallels from the 1918 flu pandemic. We conducted literature searches in the PubMed database as well as in Google Scholar. One of the main lessons learned from the 1918 flu pandemic was to employ social distancing to stop the spread of the virus. So, the global response at the start and peak of the COVID-19 pandemic was decreased hospital visits for any non-emergency cases. That led to a halt and delays in cancer (including CRC) screenings. The Medical community predicted this lag will cause more CRC cases and deaths in the future. However, reorganizing and changing screening method strategies were helpful during the ongoing pandemic. In conclusion, COVID-19 greatly affected CRC screening, including how we view the future of CRC screening. We can learn from this prospect to better prepare for future pandemics or other public health crises.

show abstract

Section: Introductionmentioning

confidence: 99%

Colorectal Cancer Screening: Impact of COVID-19 Pandemic and Possible Consequences

Harber

Zeidan

Aslam

2021

Life

View full text Add to dashboard Cite

show abstract

“…Such a difference was mainly due to the higher cost of drugs in the FOLFOX6+Bevacizumab regimen group. The results of the studies by Sehnalova et al from the perspective of the healthcare providers (2020) 54 and Pathak et al (2018) 55 showed that the direct medical costs of the group taking Bevacizumab was higher than the one taking Cetuximab, mostly due to the costs of chemotherapy drugs. However, the results of Shida et al's study (2018) 38 from the public medical care viewpoint showed that the mFOLFOX6+Cetuximab treatment arm was more expensive than the other arms, which is contrary to the results of the present study.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran

et al. 2023

View full text Add to dashboard Cite

Background Colorectal cancer is one of the most common cancers in the world, with about one million cases diagnosed annually. Various treatment methods can be used to treat colorectal cancer, including chemotherapy with different drug regimens. Considering the need to opt for more effective and less expensive drugs in the treatment of this disease, the present study aimed to compare the cost-effectiveness of FOLFOX6+Bevacizumab with FOLFOX6+Cetuximab in patients with stage IV colorectal cancer referred to medical centers in Shiraz, Iran, in 2021. Materials and Methods Using a decision tree, the cost-effectiveness and cost-utility of the 2 drug regimens were compared in all studied patients through the census method. Having a societal perspective, this study considered direct medical costs, direct non-medical costs, and indirect costs. The effectiveness indicators included the rate of major response to the drug combination used and the Quality-adjusted Life Year (QALY). The data were analyzed using Treeage 2011 and Excel 2016 software. In order to ensure the robustness of the results, one-way and probabilistic sensitivity analyses were performed as well. Results The results showed that the expected costs, the effectiveness (major response rate), and the QALYs of the FOLFOX6+Bevacizumab drug regimen were $16746.13(USD), .49, and .19, respectively, and those of the FOLFOX6+Cetuximab regimen were, respectively, $15191.05 (USD), .68, and .22. Therefore, FOLFOX6+Cetuximab compared to FOLFOX6+Bevacizumab was less costly and more effective and had a greater QALY, thus being considered as the dominant option. Also, the results of the sensitivity analyses showed that there was a bit of uncertainty. Conclusion Considering that the FOLFOX6+Cetuximab regimen was more cost-effective, it is suggested to be prioritized in preparing clinical guidelines for Iranian colorectal cancer patients. In addition, increasing the basic and supplementary insurance coverage for this drug combination as well as the use of remote technology to guide patients by oncologists can be solutions to reduce direct and indirect costs of the patients.

show abstract

“…Previous economic reviews of bevacizumab in patients with mCRC in the United States of America, the United Kingdom, Canada, Australia and Israel indicated a lack of cost-effectiveness [9,18,19], rGBM in Canada [28], mCC in the USA [46], and ovarian cancer in Canada and Belgium [3,35] and a systematic evaluation including ten countries reported that the costeffectiveness of bevacizumab in NSCLC was inconclusive [29]. High proportion of costs with targeted therapies as bevacizumab in the first line in Wild type Kirsten ras oncogene (WT KRAS) patients with mCRC could make the national health system unsustainable in some countries [44]. We found that most patients treated with bevacizumab were suffering of colorectal cancer (50.84%) and more than half were males (209, 59.54%).…”

Section: Direct Costs On Monthsmentioning

confidence: 99%

The Direct Costs Burden of Bevacizumab in South-West Romania

GHIMPĂU¹

2022

FARMACIA

View full text Add to dashboard Cite

As costs for cancer treatment increase with the reimbursement of new treatments and increasing of patients' number, prevention and prior detection efforts become even more cost-effective and potentially cost saving. The global economic burden of cancer is mostly unknown. Even though bevacizumab is one of the most prescribed and used angiogenesis inhibitors, it is among the most expensive drugs. This study aimed to generate statistical analyses of the total amounts reimbursed by the Romanian National Health Insurance Fund for treating cancer with Avastin ® in Dolj County, Romania, from January 1 st , 2020 to March 31 st , 2021. We aimed to estimate the real-world incremental costs associated with the use of bevacizumab for metastatic breast cancer, advanced non-small cell lung cancer, metastatic cancer of the colon or rectum, ovarian cancer, advanced renal cell cancer, and cervical cancer. From the total of 351 patients treated with bevacizumab, 114 (31.67%) had colon cancer and 69 (19.17%) had rectum cancer. After we investigated the economic burden of bevacizumab, we observed the highest percentage for the malignant tumour of the colon from all the direct costs. We compared the costs of bevacizumab treatment on diseases and months, observing the highest burden for colon cancer in almost all the months. Molecules such as bevacizumab are adding an appreciable cost burden to the public funded Health Care System and more studies that evaluate their cost-effectiveness are needed. RezumatPe măsură ce costurile tratamentelor pentru cancer cresc, eforturile de prevenție și depistare precoce devin cost-eficiente și pot reduce costurile. Povara economică globală a cancerului este în mare parte necunoscută. Cu toate că bevacizumab este unul dintre cei mai prescriși și utilizați inhibitori ai angiogenezei, el este și printre cele mai scumpe medicamente. Scopul studiului a fost generarea de analize statistice ale sumelor rambursate de Fondul Național de Asigurări de Sănătate pentru tratarea cancerului cu Avastin ® în județul Dolj, România, de la 1 martie 2020 până la 31 martie 2021. Am realizat o analiză economică pentru a estima costurile incrementale asociate administrării de bevacizumab pentru cancer de sân metastatic, de colon sau rect, cancer pulmonar avansat fără celule mici, cancer avansat renal, ovarian și de col uterin. Dintre cei 351 de pacienți tratați cu bevacizumab, 114 (31,67%) au prezentat cancer de colon și 69 (19,17%) cancer de rect. Investigând povara economică prezentată de bevacizumab, am observat că procentul cel mai mare al costurilor directe a fost pentru cancerul de colon. Am comparat costurile tratamentului cu bevacizumab în funcție de categoria de boală și de luna prescrierii, observând că povara economică cea mai ridicată a fost în aproape toate lunile în cazul neoplasmului de colon. Molecule precum bevacizumab adaugă o povară economică însemnată asupra costurilor suportate de către Sistemului Național de Sănătate finanțat din fonduri publice și sunt necesare mai multe studii pentru evaluarea renta...

show abstract

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

Cited by 5 publications

References 23 publications

Colorectal Cancer Screening: Impact of COVID-19 Pandemic and Possible Consequences

Colorectal Cancer Screening: Impact of COVID-19 Pandemic and Possible Consequences

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran

The Direct Costs Burden of Bevacizumab in South-West Romania

Contact Info

Product

Resources

About